Mustang Bio Stock Forecast, Price & News

Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

Is Mustang Bio a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mustang Bio stock.
View analyst ratings for Mustang Bio or view top-rated stocks.

How has Mustang Bio's stock price been impacted by Coronavirus?

Mustang Bio's stock was trading at $2.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MBIO shares have decreased by 11.5% and is now trading at $2.08.
View which stocks have been most impacted by COVID-19.

When is Mustang Bio's next earnings date?

Mustang Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Mustang Bio.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) posted its earnings results on Friday, November, 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01.
View Mustang Bio's earnings history.

What price target have analysts set for MBIO?

4 Wall Street analysts have issued 1 year target prices for Mustang Bio's shares. Their forecasts range from $7.00 to $13.00. On average, they anticipate Mustang Bio's stock price to reach $10.33 in the next year. This suggests a possible upside of 396.8% from the stock's current price.
View analysts' price targets for Mustang Bio or view top-rated stocks among Wall Street analysts.

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the following people:

• Manuel Litchman, President, Chief Executive Officer & Director (LinkedIn Profile)
• Brian Achenbach, Senior Vice President-Finance & Controller (LinkedIn Profile)
• Knut Niss, Chief Technology Officer
• Robyn M. Hunter, Secretary & Treasurer
• Jaclyn Jaffe, Head-Investor Relations

Who are some of Mustang Bio's key competitors?

Some companies that are related to Mustang Bio include Aclaris Therapeutics (ACRS), POINT Biopharma Global (PNT), Northwest Biotherapeutics (NWBO), Dyne Therapeutics (DYN), Praxis Precision Medicines (PRAX), Y-mAbs Therapeutics (YMAB), Akero Therapeutics (AKRO), Janux Therapeutics (JANX), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), Lexicon Pharmaceuticals (LXRX), Chinook Therapeutics (KDNY), Kronos Bio (KRON), Affimed (AFMD) and Cara Therapeutics (CARA).
View all of MBIO's competitors.

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu Biopharma (AYTU) and (KDMN).

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.49%), Geode Capital Management LLC (1.47%), Two Sigma Advisers LP (1.35%), Dimensional Fund Advisors LP (1.16%), Two Sigma Investments LP (1.04%) and GSA Capital Partners LLP (0.61%). Company insiders that own Mustang Bio stock include Brian Achenbach, Lindsay A Md Rosenwald and Manuel Md Litchman.
View institutional ownership trends for Mustang Bio.

Which institutional investors are selling Mustang Bio stock?

MBIO stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Two Sigma Investments LP, Two Sigma Advisers LP, Oppenheimer & Co. Inc., California State Teachers Retirement System, and Jane Street Group LLC.
View insider buying and selling activity for Mustang Bio or view top insider-selling stocks.

Which institutional investors are buying Mustang Bio stock?

MBIO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Russell Investments Group Ltd., GSA Capital Partners LLP, Goldman Sachs Group Inc., Geode Capital Management LLC, Telemetry Investments L.L.C., BlackRock Inc., and Hsbc Holdings PLC. Company insiders that have bought Mustang Bio stock in the last two years include Lindsay A Md Rosenwald, and Manuel Md Litchman.
View insider buying and selling activity for Mustang Bio or or view top insider-buying stocks.

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $2.08.

How much money does Mustang Bio make?

Mustang Bio has a market capitalization of $194.33 million. The company earns $-60.01 million in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Mustang Bio have?

Mustang Bio employs 62 workers across the globe.

What is Mustang Bio's official website?

The official website for Mustang Bio is www.mustangbio.com.

Where are Mustang Bio's headquarters?

Mustang Bio is headquartered at 377 PLANTATION STREET, WORCESTER MA, 01605.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company can be reached via phone at (781) 652-4500 or via email at [email protected].